{
    "2020-12-09": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Former Allergan CEO: Pfizer's $19.50 COVID-19 vaccine dose price 'is a pretty good bargain'",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "vaccine",
                        "price",
                        "bargain"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "10 Dividend Stocks Warren Buffett Likes the Most",
                "features": {
                    "keywords": [
                        "dividend",
                        "Warren Buffett",
                        "stocks"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "financial services",
                        "investing"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Upadacitinib (RINVOQâ„¢) Meets Primary and All Ranked Secondary Endpoints in First Phase 3 Induction Study in Ulcerative Colitis",
                "features": {
                    "keywords": [
                        "Upadacitinib",
                        "RINVOQ",
                        "Phase 3",
                        "Ulcerative Colitis",
                        "Endpoints"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}